True about BCR-ABL ‘trials’ are all except:
**Core Concept**
The BCR-ABL fusion gene is a result of a translocation between chromosomes 9 and 22, creating the Philadelphia chromosome, which is a hallmark of Chronic Myeloid Leukemia (CML) and some cases of Acute Lymphoblastic Leukemia (ALL). This fusion leads to the production of a tyrosine kinase enzyme with uncontrolled activity.
**Why the Correct Answer is Right**
The correct answer choice is not provided, however, BCR-ABL trials typically involve tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib, which specifically target the BCR-ABL tyrosine kinase, leading to inhibition of the proliferation of leukemic cells.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific details of option A, it's challenging to provide a precise explanation, but generally, incorrect options might include statements about BCR-ABL trials that do not align with the use of TKIs or the pathophysiology of CML/ALL.
**Option B:** Similarly, without specifics, option B could be incorrect if it suggests an inappropriate or ineffective treatment strategy for BCR-ABL positive leukemias.
**Option C:** This option might be incorrect if it proposes a mechanism of action or a clinical application of BCR-ABL targeted therapies that is not supported by evidence.
**Option D:** Option D could be incorrect for reasons similar to options A, B, and C, including inaccuracies regarding trial design, patient selection, or outcomes in BCR-ABL targeted therapy trials.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that the introduction of TKIs has significantly improved the prognosis of patients with CML, making it a model for targeted cancer therapy.
**Correct Answer:**